The table below shows 4D Molecular Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$68.13M
-$47.76M
-$29.09M
-$27.91M
-$23.55M
-$15.37M
Capital expenditure
-
$631.00K
$710.00K
$1.01M
$6.41M
$642.00K
Investing cash flow
$68.89M
$31.95M
-$263.26M
$43.13M
-$54.11M
-$642.00K
Dividends paid
-
-
-
-
FDMT operating cash flow (10-K history)
4D Molecular Therapeutics, Inc. reported operating cash flow of -$109.08M for fiscal year 2025. That is up 18.9% from -$134.59M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$36.71M (FY 2019) to -$109.08M. Figures come from the company's audited annual reports as filed with the SEC.